Efficacy of behavioral activation in reducing fear of cancer recurrence in non-small cell lung cancer patients: a randomized controlled trial

行为激活疗法降低非小细胞肺癌患者癌症复发恐惧的疗效:一项随机对照试验

阅读:2

Abstract

Fear of cancer recurrence (FCR) is a significant risk factor affecting treatment outcomes and prognosis in non-small cell lung cancer (NSCLC) survivors. Behavioral activation (BA), a structured therapeutic approach based on cognitive-behavioral therapy (CBT) principles, has demonstrated efficacy in alleviating psychological distress among cancer patients. This study aims to investigate the effect of BA on FCR in patients with NSCLC and explore the underlying mechanisms. A total of 82 eligible patients were randomly assigned to either the intervention group (BA) (n = 41) or the usual care group (CAU) (n = 41). Assessments were conducted at baseline (T0), week 4 (T1), and week 8 (T2) using the Cancer Recurrence Fear Scale-Brief Form (FCRI-SF), the Hospital Anxiety and Depression Scale (HADS), the Brief Resilient Coping Scale (BRCS), and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) version 3.0. Negative emotions (depression and anxiety), as well as resilient coping, were identified as potential mediators. The intervention effect and its potential mediating effects were analyzed using generalized estimating equations (GEE). GEE analysis revealed significantly lower FCR scores in the BA group at weeks 4 and 8 (Group*T1: Wald X(2) = 25.79, P < 0.001; Group*T2: Wald X(2) = 59.59, P < 0.001). Depression and anxiety scores decreased over time in the BA group and remained consistently lower than those in the usual care group (depression: Group*T1 Wald X(2) = 34.67, P < 0.001; Group*T2 Wald X(2) = 56.05, P < 0.001; anxiety: Group*T1 Wald X(2) = 36.22, P < 0.001; Group*T2 Wald X(2) = 64.85, P < 0.001). Scores for resilient coping and quality of life increased over time in the BA group and were significantly higher than those in the usual care group (resilient coping: Group*T1 Wald X(2) = 19.49, P < 0.001; Group*T2 Wald X(2) = 66.19, P < 0.001; quality of life: Group*T1 Wald X(2) = 19.86, P < 0.001; Group*T2 Wald X(2) = 64.46, P < 0.001). Furthermore, negative emotions (depression and anxiety), as well as resilient coping, were found to mediate the effect of BA on changes in FCR. The BA intervention can alleviate FCR symptoms and improve the quality of life in NSCLC patients by reducing negative emotions (depression and anxiety) and enhancing resilient coping.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。